A Phase 3 interventional study of OnabotulinumtoxinA in Platysma Prominence, sponsored by AbbVie. Completed at 29 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-12-05.
Sponsored by AbbVie · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This is a Phase 3, open-label extension study to evaluate the long-term safety of repeat BOTOX treatments in adult participants with Platysma Prominence. Participants who completed the lead-in Phase 3 Study M21-309 and met eligibility requirements could enroll in this open-label extension study.
Planned study enrollment was approximately 270 participants. Participants who met treatment criteria could receive up to 3 administrations of BOTOX. Day 1 (study entry) was the same day as Day 120/study exit visit of the lead-in Phase 3 study. The first administration of study drug could occur at the Day 1 visit, and the last administration of study drug could occur at the Day 180 visit (60 days prior to Day 240/study exit). Once a subject was enrolled in this study, monthly follow-up visits occurred.
AbbVie is the lead sponsor of 977 studies on the registry; 136 are open to participants now.
Of its 359 completed or terminated interventional studies of FDA-regulated products, 215 (60%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BOTOX (OnabotulinumtoxinA) will be injected into the platysma muscle for up to 3 Cycles during study M21-323
Drug: OnabotulinumtoxinA
Intramuscular Injection
Also known as: BOTOX
Number of Participants With Adverse Events
An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a casual relationship with this treatment.
Time frame: 371 days (from enrollment in the lead-in study M21-309 through end of study M21-323)
A total of 292 participants were enrolled at 28 sites in the United States and Canada. All participants received at least 1 dose of open-label BOTOX and were included in the intent-to-treat (ITT) and safety populations.
| Milestone | BOTOX |
|---|---|
| Started | 292 |
| Completed | 262 |
| Not completed | 30 |
| Withdrew: Lost to follow-up | 12 |
| Withdrew: Withdrawal by subject | 14 |
| Withdrew: Pregnancy | 1 |
| Withdrew: Other, not specified | 3 |
An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a casual relationship with this treatment.
| Participants | Placebo (Lead-in) | BOTOX (Cycle 1) | BOTOX (Cycle 2) | BOTOX (Cycle 3) | BOTOX (Cycle 4) | BOTOX (All Treatment Cycles) | Total |
|---|---|---|---|---|---|---|---|
| Number of Participants With Adverse Events | 33 | 74 | 46 | 26 | 11 | 111 | 127 |
Collected over All-cause mortality and adverse event tables include events reported from enrollment in M21-323 to the end of study. The median time participants were followed was 239.0 days.. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| BOTOX | 0/292 (0%) | 2/292 (0.7%) | 42/292 (14.4%) |
| Event | BOTOX |
|---|---|
| CELLULITISInfections and infestations | 1/292 |
| HYPONATRAEMIAMetabolism and nutrition disorders | 1/292 |
| Event | BOTOX |
|---|---|
| COVID-19Infections and infestations | 22/292 |
| INJECTION SITE BRUISINGGeneral disorders | 12/292 |
| NASOPHARYNGITISInfections and infestations | 12/292 |
ITT Population
| Age, Categorical(Participants) | BOTOX |
|---|---|
| <=18 years | 0 |
| Between 18 and 65 years | 278 |
| >=65 years | 14 |
| Age, Continuous(Years) | BOTOX |
|---|---|
| Mean | 49.6 ± 9.76 |
| Sex: Female, Male(Participants) | BOTOX |
|---|---|
| Female | 273 |
| Male | 19 |
| Ethnicity (NIH/OMB)(Participants) | BOTOX |
|---|---|
| Hispanic or Latino | 31 |
| Not Hispanic or Latino | 261 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | BOTOX |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 15 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 12 |
| White | 265 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols, analyses plans, clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: For details on when studies are available for sharing visit https://vivli.org/ourmember/abbvie/
Access criteria: Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous independent scientific research, and will be provided following review and approval of a research proposal and statistical analysis plan and execution of a data sharing statement. Data requests can be submitted at any time after approval in the US and/or EU and a primary manuscript is accepted for publication. For more information on the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/
Data sharing details ↗ · vivli.org
Ran from Nov 2021 to primary completion in Aug 2023, 21 months.
Results were first posted in Dec 2024, 1 year 3 months after primary completion. A results delay was requested in May 2024.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Botulinum toxin type A